- All > Medicine Information and Evidence for Policy > Medicines Policy
- All > Medicine Access and Rational Use > Good Governance for Medicines
- All > Medicine Programme Coordination > Programme Coordination
- Keywords > access to medicines
- Keywords > accountability - pharmaceutical sector
- Keywords > availability, affordability, and quality of pharmaceutical products
- Keywords > corruption
- Keywords > key achievements
- Keywords > legal framework
- Keywords > MeTA - The Medicines Transparency Alliance
- Keywords > multi-stakeholder approach
- Keywords > pharmaceutical sector - good governance
- Keywords > transparency
(2016; 12 pages)
The Medicines Transparency Alliance (MeTA) began as a pilot in Peru in 2008. It aimed to contribute to good governance, transparency and accountability across the medicines chain, through the engagement of all stakeholders with an interest in the medicines market.
The programme was spearheaded by the Ministry of Health (MOH). It established a council, which was led by the pharmaceutical regulator, the General Directorate of Medicines, Supplies and Drugs (DIGEMID). The council was made up of 15 member organizations from civil society, the public sector, the private sector and a representative from the Pan American Health Organization (PAHO) country office. It has met fortnightly. It has led MeTA Peru’s programme of work, which has included the development of monitoring systems for medicine price, quality and availability, and measures to improve public procurement. Committees have been created to oversee each area of work, each with representatives from the different sectors.
Peru has been one of seven countries to undertake the MeTA intiative. The programme has also been active in Ghana, Jordan, Kyrgyzstan, the Philippines, Uganda and Zambia. It has been funded by the UK Government through the Department for International Development.